Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hauschild

Showing results (951-960 of 1,351) with videos related to

Pageof 136
Sort By:
Developmental Cell|December 17, 2021
WASp triggers mechanosensitive actin patches to facilitate immune cell migration in dense tissuesFlorian Gaertner, Patricia Reis-Rodrigues, Ingrid de Vries, et al.
Pharmaceuticals (Basel, Switzerland)|October 23, 2021
Activity of New Synthetic (2-Chloroethylthio)-1,4-naphthoquinones in Prostate Cancer CellsSergey A Dyshlovoy, Dmitry N Pelageev, Lea S Jakob, et al.
Proteomics|April 27, 2017
Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalininSergey A Dyshlovoy, Katharina Otte, Simone Venz, et al.
International Journal of Cardiology|October 15, 2016
Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting - A feasibility and safety studyPhiline J Köln, Bruno Scheller, Houng Bang Liew, et al.
Revue Medicale Suisse|February 7, 2012
[Pediatrics]C J Fischer, E Giannoni, A C Truttmann, et al.
The British Journal of Dermatology|February 19, 2009
Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studiesA Hauschild, E Stockfleth, G Popp, et al.
Breast Cancer Research and Treatment|August 11, 2010
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio studyJens Huober, Gunter von Minckwitz, Carsten Denkert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2013
Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-upSelma Ugurel, Thomas Mentzel, Jochen Utikal, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) studyJean Jacques Grob, Thomas Jouary, Brigitte Dréno, et al.
Environment International|February 14, 2015
Exploring the planetary boundary for chemical pollutionMiriam L Diamond, Cynthia A de Wit, Sverker Molander, et al.
Pageof 136

Showing results (951-960 of 1,351) with videos related to

Sort By:
Pageof 136
Developmental Cell|December 17, 2021
WASp triggers mechanosensitive actin patches to facilitate immune cell migration in dense tissuesFlorian Gaertner, Patricia Reis-Rodrigues, Ingrid de Vries, et al.
Pharmaceuticals (Basel, Switzerland)|October 23, 2021
Activity of New Synthetic (2-Chloroethylthio)-1,4-naphthoquinones in Prostate Cancer CellsSergey A Dyshlovoy, Dmitry N Pelageev, Lea S Jakob, et al.
Proteomics|April 27, 2017
Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalininSergey A Dyshlovoy, Katharina Otte, Simone Venz, et al.
International Journal of Cardiology|October 15, 2016
Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting - A feasibility and safety studyPhiline J Köln, Bruno Scheller, Houng Bang Liew, et al.
Revue Medicale Suisse|February 7, 2012
[Pediatrics]C J Fischer, E Giannoni, A C Truttmann, et al.
The British Journal of Dermatology|February 19, 2009
Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: results of two randomized controlled phase III studiesA Hauschild, E Stockfleth, G Popp, et al.
Breast Cancer Research and Treatment|August 11, 2010
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio studyJens Huober, Gunter von Minckwitz, Carsten Denkert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2013
Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-upSelma Ugurel, Thomas Mentzel, Jochen Utikal, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) studyJean Jacques Grob, Thomas Jouary, Brigitte Dréno, et al.
Environment International|February 14, 2015
Exploring the planetary boundary for chemical pollutionMiriam L Diamond, Cynthia A de Wit, Sverker Molander, et al.
Pageof 136